Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
Go back to Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies| (NASDAQ: BMEA) | Delayed: 1.23 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.23 | 52 Week High | $ | |||
| Open | $1.23 | 52 Week Low | $ | |||
| Day High | $1.23 | P/E | N/A | |||
| Day Low | $1.23 | EPS | $ | |||
| Volume | 53 | |||||
